InGeneron

02/04/2026

InGeneron is pleased to announce successful certification under the EU Medical Device Regulation (MDR) (EU) 2017/745.

CE Certification was achieved following a comprehensive review of our Technical Documentation and ISO 13485 Quality Management System.

This milestone reflects InGeneron’s long-standing commitment to quality, regulatory rigor, and patient safety, and supports our continued ability to serve physicians and patients across the European Union.

hashtag hashtag hashtag hashtag hashtag

07/23/2025

📢 InGeneron Publishes Landmark Study Demonstrating Structural Tendon Regeneration with Autologous Cell Therapy System.

This study completes a decade of scientific validation of our therapeutic approach through peer-reviewed data:

✅ Consistent cell characterization
✅ In Vivo Regeneration
✅ Human Biopsy Evidence
✅ Clinical Trial Data

🔬 Read the full announcement:
👉 https://ingeneron.com/?p=2929

11/14/2023

InGeneron reports positive long-term results for its cell therapy in partial-thickness rotator cuff tears. The randomized controlled trial, published in Nature's Scientific Reports, met primary endpoints, and finds statistically significant durable patient benefit 3.4 years post-treatment.

To read the full press release, please visit

Randomized controlled trial meets primary endpoint and finds statistically significant durable patient benefit 3.4 years post-treatment.

09/21/2023

InGeneron will be attending The MedTech Conference in Anaheim, CA from October 9-11, 2023. We are excited to showcase our mission at the largest gathering of medical technology professionals in North America. We look forward to connecting with existing partners and fostering new collaborations to drive the future of regenerative medicine.

09/04/2023

Happy Labor Day! Today, we celebrate the remarkable contributions of our dedicated team in the science and technology industry. At InGeneron, we are grateful for their hard work and unwavering commitment to innovation. Together, we are shaping the future.

08/09/2023

We're excited to announce the growth of our team here at InGeneron! Last year was a year of tremendous progress for us, and we're thrilled to welcome Annette Zinn , J.D., Ph.D. as our Director of Regulatory Affairs. Annette joined our team in 2022 and brings over 40 years of regulatory experience in the medical device industry. We're confident that Annette's expertise will help us continue to advance our mission and bring lifechanging treatments to patients in need. Welcome to the team, Annette!

07/26/2023

InGeneron's pipeline is developing advanced regenerative therapies for a wide range of diseases and injuries. Discover how our innovative technologies are changing the game at https://ingeneron.com/pipeline/.

07/14/2023

InGeneron is committed to advancing the field of regenerative medicine through our innovative cellular therapy products. Learn more about our technology and approach at https://ingeneron.com/

07/12/2023

With an extensive background of over 20 years in research, InGeneron is dedicated to the development of groundbreaking, evidence-based cell therapies. Our focus is on unlocking the potential of regenerative cells within each patient, to enable minimally invasive treatments that have the potential to set new therapeutic standards. Presently, our efforts focus on creating therapies for patients impacted by orthopedic conditions, and we are actively conducting several clinical trials to assess the potential disease-modifying effects of our technology. As we strive to meet the highest regulatory standards, our therapies are subject to rigorous review by the FDA, emphasizing our commitment to developing treatments supported by clinical evidence. For more information about InGeneron's mission and our ongoing clinical trials, please visit our website:
https://ingeneron.com/

InGeneron is a clinical-stage biotechnology company developing cell-based therapies to redefine the standard of care in orthopedics.

07/10/2023

InGeneron is led by an international team of bold innovators creating the next generation of life-changing therapeutics. One of the most influential people behind this new age of regenerative medicine is our Executive Chairman, Dr. Eckhard Alt.

Dr. Alt is a frequent reviewer and serves on the editorial boards of respected journals. From 2001 to 2007, he was president of the Cardiac Electrophysiology Society. He has organized major national and international congresses; authored more than 500 publications in peer-reviewed journals, books, or book chapters; and has acquired more than 600 worldwide patents, primarily in the fields of stem cells, electrophysiology, and interventional cardiology.

Learn more about his story and the rest of our team by visiting our website: https://ingeneron.com/leadership/